bevacizumab for her2-negative metastatic breast cancer ......source: miles dw et al. sabcs...
TRANSCRIPT
![Page 1: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases](https://reader033.vdocuments.mx/reader033/viewer/2022060712/607863877f12181443423d74/html5/thumbnails/1.jpg)
For more visit ResearchToPractice.com/5MJCBreast
AVADO — Final Overall Survival Results of First-Line Docetaxel in Combination with Escalating Doses of Bevacizumab for HER2-Negative Metastatic Breast CancerPresentation discussed in this issue:
Miles DW et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, Phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2009;Abstract 41.
Editor’s comment: At the end of this slide set are several graphics with results from a recent Patterns of Care study of 100 US-based medical oncologists.
Slides from a presentation at SABCS 2009
![Page 2: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases](https://reader033.vdocuments.mx/reader033/viewer/2022060712/607863877f12181443423d74/html5/thumbnails/2.jpg)
For more visit ResearchToPractice.com/5MJCBreast
![Page 3: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases](https://reader033.vdocuments.mx/reader033/viewer/2022060712/607863877f12181443423d74/html5/thumbnails/3.jpg)
For more visit ResearchToPractice.com/5MJCBreast
![Page 4: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases](https://reader033.vdocuments.mx/reader033/viewer/2022060712/607863877f12181443423d74/html5/thumbnails/4.jpg)
For more visit ResearchToPractice.com/5MJCBreast
![Page 5: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases](https://reader033.vdocuments.mx/reader033/viewer/2022060712/607863877f12181443423d74/html5/thumbnails/5.jpg)
For more visit ResearchToPractice.com/5MJCBreast
![Page 6: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases](https://reader033.vdocuments.mx/reader033/viewer/2022060712/607863877f12181443423d74/html5/thumbnails/6.jpg)
For more visit ResearchToPractice.com/5MJCBreast